IP Library Granted Patent US 9,670,459
Granted Patent B2
US 9,670,459 · App. 13/816,001 · Granted Jun 6, 2017

Production method for cell populations

Inventors: Katsuyuki Dodo (Otsu, JP); Hideto Chono (Otsu, JP); Junichi Mineno (Otsu, JP)
Assignee: TAKARA BIO INC.
C12N5/0636A61K35/17C12N5/0637A61K35/12C12N2501/2304C12N2501/998C12N2510/00
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,670,459
App. No.
13/816,001
Granted
Jun 6, 2017
Kind
B2
Abstract

The present invention addresses the problem of providing cell populations having a high proportion of CD4-positive naive T cells and/or CD4-positive central memory T cells, and a production method thereof. The present invention provides a production method for CD4-positive T cell populations which is characterized by using anti-CD3 antibodies, fibronectin fragments, and Interleukin-4. The method is characterized not only by the attainment of a cell group with a high proportion of CD4-positive naive T cells and/or CD4-positive central memory T cells, but also by a high bulk yield.

Claims (11)

1. A method of producing CD4-positive naïve T cells and/or CD4-positive central memory T cells expressing CD62L and/or CCR7, the method comprising the following steps:

(1) removing CD8-positive T cells or collecting CD4-positive T cells from a cell population containing T cells; and

(2) culturing the cell population obtained by the step (1) in the presence of the following (A) and (B), and for the whole period or a partial period during the culture and/or during expansion after the culture, culturing the cell population in the presence of the following (C):

(A) at least one polypeptide selected from the group consisting of fibronectin, fibronectin fragments and their mixtures,

(B) a CD3 ligand, or a CD3 ligand and a CD28 ligand,

(C) interleukin-4 in an amount of 0.01 to 100 ng/ml.

2. The method according to claim 1 , wherein the step (2) is a step of culturing the cell population in the presence of (A) and (B) and in the presence of (C), and then expanding the obtained cell population in the presence of (C).

3. The method according to claim 1 , wherein the step (2) is a step of culturing the cell population in the presence of (A) and (B) and in the absence of (C), and then expanding the obtained cell population in the presence of (C).

4. The method according to claim 1 , wherein the step (2) is a step of culturing the cell population in the presence of (A) and (B) and in the presence of (C), and then expanding the obtained cell population in the absence of (C).

5. The method according to claim 1 , further comprising a step for foreign gene transfer.

6. The method according to claim 1 , wherein the cell population containing T cells in step (1) is peripheral blood mononuclear cells (PBMC).

Assignments (3)
CHANGE OF ADDRESS Recorded Jun 29, 2016
From: TAKARA BIO INC.
To: TAKARA BIO INC.
Reel/Frame 039206/0281 →
CORRECTIVE ASSIGNMENT TO CORRECT THE ATTORNEY DOCKET NUMBER PREVIOUSLY RECORDED ON REEL 029782 FRAME 0531. ASSIGNOR(S) HEREBY CONFIRMS THE ATTORNEY DOCKET NUMBER. Recorded Mar 11, 2013
From: DODO, KATSUYUKI; CHONO, HIDETO; MINENO, JUNICHI
To: TAKARA BIO INC.
Reel/Frame 029967/0547 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 8, 2013
From: DODO, KATSUYUKI; CHONO, HIDETO; MINENO, JUNICHI
To: TAKARA BIO INC.
Reel/Frame 029782/0531 →
Priority Claims (1)
JP 2010-179702 · Aug 10, 2010 · national
Continuity (1)
Related Publication 20130142766A1 · Jun 6, 2013